Precision Organ Chip oncology platform accurately and actionably predicts chemotherapy responses of patients suffering from esophageal adenocarcinoma

Manuscript title: Patient-derived esophageal adenocarcinoma organ chip: a physiologically relevant platform for functional precision oncology Publication date: 23 May, 2025 Journal: Journal of Translational Medicine Patient-specific EAC treated on-a-chip (Fig. 5 A.i. and A.ii): Image 1 caption: These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy. On the left, the researchers used immunofluorescence stainings to visualize cellular markers of esophageal adenocarcinoma cells in the upper EAC channel and a stromal marker in the lower stromal channel, indicating chemosensitivity in the cancer chip on the left and chemoresistance in the cancer chip on the right (bottom row). On the right, they looked at the same Cancer Chips using scanning electron microscopy, with the cell and tissue morphologies showing chemotherapy sensitivity and resistance. Credit: Wyss Institute at Harvard University Graphical Abstract: This graphical abstract explains how the team correlated the effects of a chemotherapy in patients suffering from esophageal adenocarcinoma with findings they obtained using their precision oncology Organ Chip platform. The study demonstrates the utility of the platform as a much-needed personalized medicine tool to improve chemotherapy these patients. Credit: Wyss Institute at Harvard University